Literature DB >> 32441921

Super-Resolution Fluorescence Imaging Reveals That Serine Incorporator Protein 5 Inhibits Human Immunodeficiency Virus Fusion by Disrupting Envelope Glycoprotein Clusters.

Yen-Cheng Chen1, Chetan Sood1, Mariana Marin1, Jesse Aaron2, Enrico Gratton3, Khalid Salaita4, Gregory B Melikyan1,5.   

Abstract

Serine incorporator protein 5 (SERINC5) is the host antiretroviral factor that reduces HIV-1 infectivity by incorporating into virions and inhibiting the envelope glycoprotein (Env) mediated virus fusion with target cells. We and others have shown that SERINC5 incorporation into virions alters the Env structure and sensitizes the virus to broadly neutralizing antibodies targeting cryptic Env epitopes. We have also found that SERINC5 accelerates the loss of Env function over time compared to control viruses. However, the exact mechanism by which SERINC5 inhibits HIV-1 fusion is not understood. Here, we utilized 2D and 3D super-resolution microscopy to examine the effect of SERINC5 on the distribution of Env glycoproteins on single HIV-1 particles. We find that, in agreement with a previous report, Env glycoproteins form clusters on the surface of mature virions. Importantly, incorporation of SERINC5, but not SERINC2, which lacks antiviral activity, disrupted Env clusters without affecting the overall Env content. We also show that SERINC5 and SERINC2 also form clusters on single virions. Unexpectedly, Env and SERINC molecules exhibited poor codistribution on virions, as evidenced by much greater Env-SERINC pairwise distances compared to Env-Env distances. This observation is inconsistent with the previously reported interaction between Env and SERINC5 and suggests an indirect effect of SERINC5 on Env cluster formation. Collectively, our results reveal a multifaceted mechanism of SERINC5-mediated restriction of HIV-1 fusion that, aside from the effects on individual Env trimers, involves disruption of Env clusters, which likely serve as sites of viral fusion with target cells.

Entities:  

Keywords:  DBSCAN; HIV-1 restriction; SERINC5; envelope glycoprotein clustering; super-resolution microscopy; viral fusion

Mesh:

Substances:

Year:  2020        PMID: 32441921      PMCID: PMC8274448          DOI: 10.1021/acsnano.0c02699

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  56 in total

1.  Structural organization of authentic, mature HIV-1 virions and cores.

Authors:  John A G Briggs; Thomas Wilk; Reinhold Welker; Hans-Georg Kräusslich; Stephen D Fuller
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

2.  Distinct requirements for HIV-cell fusion and HIV-mediated cell-cell fusion.

Authors:  Naoyuki Kondo; Mariana Marin; Jeong Hwa Kim; Tanay M Desai; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

3.  The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.

Authors:  Birthe Trautz; Virginia Pierini; Rebecka Wombacher; Bettina Stolp; Amanda J Chase; Massimo Pizzato; Oliver T Fackler
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

4.  Disruption of Serinc1, which facilitates serine-derived lipid synthesis, fails to alter macrophage function, lymphocyte proliferation or autoimmune disease susceptibility.

Authors:  Edward P F Chu; Colleen M Elso; Abigail H Pollock; May A Alsayb; Leanne Mackin; Helen E Thomas; Thomas W H Kay; Pablo A Silveira; Ashley S Mansell; Katharina Gaus; Thomas C Brodnicki
Journal:  Mol Immunol       Date:  2016-12-19       Impact factor: 4.407

5.  Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells.

Authors:  Mathias Viard; Isabella Parolini; Massimo Sargiacomo; Katia Fecchi; Carlo Ramoni; Sherimay Ablan; Francis W Ruscetti; Ji Ming Wang; Robert Blumenthal
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Murine Leukemia Virus Glycosylated Gag Reduces Murine SERINC5 Protein Expression at Steady-State Levels via the Endosome/Lysosome Pathway to Counteract SERINC5 Antiretroviral Activity.

Authors:  Sunan Li; Iqbal Ahmad; Jing Shi; Bin Wang; Changqing Yu; Lixin Zhang; Yong-Hui Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

7.  Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy.

Authors:  Jakub Chojnacki; Thorsten Staudt; Bärbel Glass; Pit Bingen; Johann Engelhardt; Maria Anders; Jale Schneider; Barbara Müller; Stefan W Hell; Hans-Georg Kräusslich
Journal:  Science       Date:  2012-10-26       Impact factor: 47.728

8.  HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.

Authors:  Annachiara Rosa; Ajit Chande; Serena Ziglio; Veronica De Sanctis; Roberto Bertorelli; Shih Lin Goh; Sean M McCauley; Anetta Nowosielska; Stylianos E Antonarakis; Jeremy Luban; Federico Andrea Santoni; Massimo Pizzato
Journal:  Nature       Date:  2015-09-30       Impact factor: 49.962

9.  Super-resolution microscopy reveals specific recruitment of HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-terminal tail.

Authors:  Walter Muranyi; Sebastian Malkusch; Barbara Müller; Mike Heilemann; Hans-Georg Kräusslich
Journal:  PLoS Pathog       Date:  2013-02-28       Impact factor: 6.823

Review 10.  Mechanics of membrane fusion.

Authors:  Leonid V Chernomordik; Michael M Kozlov
Journal:  Nat Struct Mol Biol       Date:  2008-07       Impact factor: 15.369

View more
  19 in total

Review 1.  HIV-1 entry: Duels between Env and host antiviral transmembrane proteins on the surface of virus particles.

Authors:  Tomoyuki Murakami; Akira Ono
Journal:  Curr Opin Virol       Date:  2021-08-12       Impact factor: 7.121

Review 2.  Virus morphology: Insights from super-resolution fluorescence microscopy.

Authors:  Nicole C Robb
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2022-01-13       Impact factor: 6.633

3.  HIV-cell membrane fusion intermediates are restricted by Serincs as revealed by cryo-electron and TIRF microscopy.

Authors:  Amanda E Ward; Volker Kiessling; Owen Pornillos; Judith M White; Barbie K Ganser-Pornillos; Lukas K Tamm
Journal:  J Biol Chem       Date:  2020-08-11       Impact factor: 5.157

4.  HIV envelope tail truncation confers resistance to SERINC5 restriction.

Authors:  Tafhima Haider; Xenia Snetkov; Clare Jolly
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 12.779

Review 5.  HIV-1 restriction by SERINC5.

Authors:  Lucía Cano-Ortiz; Tom Luedde; Carsten Münk
Journal:  Med Microbiol Immunol       Date:  2022-03-25       Impact factor: 3.402

Review 6.  Evolutionary conflicts and adverse effects of antiviral factors.

Authors:  Daniel Sauter; Frank Kirchhoff
Journal:  Elife       Date:  2021-01-15       Impact factor: 8.140

7.  Cholesterol in the Viral Membrane is a Molecular Switch Governing HIV-1 Env Clustering.

Authors:  Jon Ander Nieto-Garai; Aroa Arboleya; Sara Otaegi; Jakub Chojnacki; Josefina Casas; Gemma Fabriàs; F-Xabier Contreras; Hans-Georg Kräusslich; Maier Lorizate
Journal:  Adv Sci (Weinh)       Date:  2020-12-21       Impact factor: 16.806

Review 8.  Towards a Quantitative Single Particle Characterization by Super Resolution Microscopy: From Virus Structures to Antivirals Design.

Authors:  Maria Arista-Romero; Silvia Pujals; Lorenzo Albertazzi
Journal:  Front Bioeng Biotechnol       Date:  2021-03-26

Review 9.  Retroviral Restriction Factors and Their Viral Targets: Restriction Strategies and Evolutionary Adaptations.

Authors:  Guney Boso; Christine A Kozak
Journal:  Microorganisms       Date:  2020-12-11

10.  Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5.

Authors:  Steven W Jin; Francis M Mwimanzi; Jaclyn K Mann; Mwebesa Bosco Bwana; Guinevere Q Lee; Chanson J Brumme; Peter W Hunt; Jeff N Martin; David R Bangsberg; Thumbi Ndung'u; Zabrina L Brumme; Mark A Brockman
Journal:  PLoS Pathog       Date:  2020-09-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.